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Downregulation of glutamic acid 
decarboxylase in Drosophila TDP-
43-null brains provokes paralysis 
by affecting the organization of the 
neuromuscular synapses
Giulia Romano1, Nikola Holodkov1, Raffaella Klima  1, Federica Grilli1, Corrado Guarnaccia1, 
Monica Nizzardo  2, Federica Rizzo2, Rodolfo Garcia1 & Fabian Feiguin1
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that affects the motor system, 
comprised of motoneurons and associated glia. Accordingly, neuronal or glial defects in TDP-43 function 
provoke paralysis due to the degeneration of the neuromuscular synapses in Drosophila. To identify the 
responsible molecules and mechanisms, we performed a genome wide proteomic analysis to determine 
differences in protein expression between wild-type and TDP-43-minus fly heads. The data established 
that mutant insects presented reduced levels of the enzyme glutamic acid decarboxylase (Gad1) and 
increased concentrations of extracellular glutamate. Genetic rescue of Gad1 activity in neurons or glia 
was sufficient to recuperate flies locomotion, synaptic organization and glutamate levels. Analogous 
recovery was obtained by treating TDP-43-null flies with glutamate receptor antagonists demonstrating 
that Gad1 promotes synapses formation and prevents excitotoxicity. Similar suppression of TDP-43 
provoked the downregulation of GAD67, the Gad1 homolog protein in human neuroblastoma cell 
lines and analogous modifications were observed in iPSC-derived motoneurons from patients carrying 
mutations in TDP-43, uncovering conserved pathological mechanisms behind the disease.
Amyotrophic lateral sclerosis (ALS) affects motoneuron performance leading to muscles denervation, wasting 
and paralysis. Although the pathological origin of the disease is not well known, defects in the solubility and 
intracellular distribution of the ribonuclear protein (RNP) TDP-43 strongly correlate with the neurological symp-
toms and histological modifications observed in the great majority of affected patients1–3. Several experimental 
manipulations have been performed in different animal models, as mouse4–7, C.elegans8,9, D.rerio10–12 as well as 
in D.melanogaster13–16, which have clearly demonstrated that the suppression of TDP-43 function is sufficient to 
reproduce the main characteristics of the disease: locomotive defects, neurodegeneration and reduced life span. 
This has raised the issue of TDP-43 playing a central role in the pathophysiological mechanisms of ALS. In this 
direction, we have recently described the initial events that lead to muscle denervation and motoneuron degen-
eration upon the acute suppression of endogenous TDP-43 protein (TBPH) in Drosophila melanogaster neurons 
or glial cells17,18. Therefore, we found that the neuronal or glial function of TBPH was similarly required to pre-
vent locomotive alterations and preserve the postsynaptic organization of the glutamate receptors (GluRIIA) 
present at the neuromuscular junctions (NMJs) of flies. These results support the idea that ALS could present a 
non-neuronal origin and, implies that alterations in TBPH function inside neurons or glial cells may contribute 
to the disease by affecting the regulations of analogous metabolic pathways13,19,20. In order to test this hypothesis 
and identify those molecules, we decided to perform a genome wide high throughput proteomic analysis by 
combining high-resolution two-dimensional (2D) gel electrophoresis with MALDI-TOF mass spectrometry. We 
reasoned that this approach would succeed in identifying mRNA target molecules regulated by TBPH at both 
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translational or post-transcriptional level, as recently suggested for the conserved microtubule binding protein 
futsch/MAP1B21. The present study reports that the enzyme glutamic acid decarboxylase 1 (Gad1) appears down-
regulated in TBPH mutant brains and describes that Gad1 function is required in neurons or non-autonomously 
in glial tissues. It promotes motoneuron synaptogenesis and muscle innervation through the correct organization 
of the glutamate receptors at the postsynaptic membranes, more specifically by limiting an excessive accumula-
tion of the glutamate neurotransmitter in the extracellular space. We also show that the TBPH-Gad1 regulatory 
relationship is conserved in human neuronal cell lines and is present in pluripotent stem cells derived from ALS 
patients carrying mutations in TDP-43. The data obtained provide novel bases to understand the pathological 
process behind the disease and open the way to novel therapeutic interventions.
Results
Proteomic analysis identifies reduced levels of Gad1 in TBPH null brains. Since mRNA levels are 
not necessarily related to actual protein expression, we decided to use two-dimensional gel electrophoresis to 
establish protein levels in wild-type vs TBPH minus flies. This approach could result in the identification of new 
molecules potentially responsible for the neurological phenotypes described in TBPH minus flies. Protein 2D 
maps of 1 day-old wild-type and TBPH null adult Drosophila heads were analyzed after normalization for sta-
tistical differences in spot intensities. The number of spots modified by 1.5 > fold was 35/1383 (Supplementary 
Fig. S1a–d). Among them we focused on those found modified in the same direction for both mutant alleles 
(tbphΔ23 and tbphΔ142) compared with the wild type flies. We also excluded spots in gel areas of heavy streaking 
and/or abnormally strong background making them unreliable, after which a total of 5 down-regulated and 2 
up-regulated spots were subjected to mass spectrometry identification (Supplementary Fig. S1d and Table 1). 
We found that one of the most significantly down-regulated spots in mutant heads corresponded to the pro-
tein glutamic acid decarboxylase Gad1 (CG14994, FBgn0004516) (Fig. 1a). This enzyme is very well conserved 
in mammals and its catalytic function is required in Drosophila embryos to regulate extracellular levels of the 
neurotransmitter glutamate and define the postsynaptic organization of the glutamatergic synapses present at 
the neuromuscular junctions (NMJ)22. Since antibodies anti-Gad1 are not available, the proteomic results were 
validated with an alternative immunodetection-based methodology. We utilized an allele of Gad1 endogenously 
tagged with EGFP after the insertion of the MiMIC cassette within its coding sequence23–25. Western blot analysis 
of Gad1MiMIC brains (w;Mi{MIC}Gad1MI09277/+) using antibodies against flag showed the presence of a specific 
band of 95 kDa. This molecular mass is consistent with the sum of Gad1 (57.8 kDa) plus the EGFP-FlAsH-
StrepII-TEV-3xFlag-tag insertion (35 kDa). The 95 kDa band was found to be clearly reduced in a TBPH minus 
background (tbphΔ23/tbphΔ23;Mi{MIC}Gad1MI09277/+) (Fig. 1b and Supplementary Fig. S6a). In support of the 
proteomic data, quantitative PCR assays revealed that the levels of Gad1 mRNA were also reduced in tbphΔ23 
and tbph∆142 loss-of-function alleles (Fig. 1c). Therefore, the downregulation of Gad1 in TBPH null heads was 
expressed at both transcriptional and translational levels.
Genetic rescue of Gad1 activity in presynaptic neurons or motoneurons recovered flies motility 
and the postsynaptic organization of neuromuscular junctions. To test whether the down-
regulation of Gad1 played any role in TBPH loss-of-function phenotypes, we utilized the GAL4/UAS system 
to increase the expression of Gad1 in TBPH minus neurons using the specific driver elav-GAL4 (tbph∆23/∆23, 
elav-GAL4;UAS-Gad1). This strategy was sufficient to partially rescue the locomotive problems observed in 
TBPH minus third instar larvae (L3) and, more surprisingly, very efficiently recovered the TBPH minus motility 
defects after the expression of UAS-Gad1 in a more restricted group of cells like motoneurons using D42-GAL4 
(tbph∆23/∆23;D42-GAL4/UAS-Gad1) (Fig. 1d). Despite the capacity of Gad1 to rescue larvae motility, we found 
that these larvae were not able to reach adult stages indicating that the overexpression of this transgene was not 
able to compensate the complete absence of TBPH. Therefore, to test whether the expression of Gad1 was also able 
to restore the normal locomotion of adult flies, similar rescue experiments were performed utilizing a hypomor-
phic allele of TBPH generated by the expression of an RNAi against this protein (tbph∆23,elav-GAL4/+;UAS-Dcr-
2,TBPH-RNAi/UAS-Gad1). Thus, our experiments showed that the overexpression of Gad1 significantly 
enhances the climbing abilities of TBPH-hypomorphic flies compared to GFP-expressing controls (Fig. 1e and 
Supplementary Fig. S2h). At the molecular level, the neuronal expression of Gad1 in TBPH mutant larvae was 
sufficient to restore the wild-type organization of the glutamate receptors in postsynaptic clusters (GluRIIA) as 
well as the homogeneous localization of the disc-large protein (Dlg) around the presynaptic boutons (Fig. 1f–i). 
On the contrary, the neuronal expression of Gad1 was not able to promote motoneuron terminal growth or 






N° of peptides 
detected
Fold change mut 
vs. control
701 CG14994 Glutamic acid decarboxylase 125 57.72/57.8 18 ↓1.83
187 CG17285 Fat body protein1, isoA 200 119.59/119.7 40 ↓4.52
324 CG17285 Fat body protein1, isoA 79 119.59/119.7 30 ↓3.04
470 CG17285 Fat body protein1, isoA 135 119.59/119.7 19 ↓1.99
216 CG2979 Yolk protein2 134 49.63/49.7 29 ↓3.21
344 CG4904 Proteasome α6 subunit 153 31.04/31.1 28 ↑4.41
851 CG4190 Heat shock gene 67Bc 113 22.17/22.2 4 ↑2.56
Table 1. The 7 modified 2D spots identified in TBPH mutants compared to control.
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in presynaptic neurons or solely in motoneurons (elav-GAL4/+;GAD-RNAi or UAS-Dcr-2/+;;D42-GAL4/
GAD-RNAi) provoked strong locomotive defects and severe alterations in the intracellular organization of the 
postsynaptic proteins Dlg and GluRIIA (Fig. 2a–f and Supplementary Fig. S3a–f). This demonstrated that Gad1 
plays a relevant role in the neurodegenerative process triggered by a TBPH dysfunction.
Figure 1. Gad1 is downregulated in TBPH-mutant flies and required for synaptogenesis. (a) Two-
dimensional electrophoresis analysis of adult heads in Drosophila revealed that the spot 701, corresponding 
to the Gad1-CG14994 protein was reduced in Δtb-23 and Δtb-142 (tbphΔ23/Δ23 and tbphΔ142/Δ142) null 
alleles compared to w1118controls. The bar graph indicates quantified spot intensities (volumes), after gel 
normalization. n = 3. (b) Western blot analysis of w1118, Gad1MiMIC (w; +/+;Mi{MIC}Gad1MI09277/+) and 
Gad1MiMIC − Δtb (w;tbphΔ23/tbphΔ23;Mi{MIC}Gad1MI09277/+). Third instar larval brains were probed with anti-
FlagM5 and alpha-tubulin antibodies. The same membrane was probe with the two antibodies and the bands of 
interest were cropped. Quantification of normalized amounts was reported below each lane. n = 3. (c) Real time 
PCR of Gad1 transcript levels normalized on Rpl11 (housekeeping) in third instar larval brains of w1118, Δtb-23 
(tbphΔ23/Δ23) and Δtb-142 (tbphΔ142/Δ142). n = 3. (d) Number of peristaltic waves between w1118, Δtb-GFP (left: 
elav-GAL4,tbphΔ23/tbphΔ23;UAS-GFP/ +; right: tbphΔ23/tbphΔ23;D42-GAL4/UAS-GFP), Δtb-Gad1 (left side: 
elav-GAL4,tbphΔ23/tbphΔ23;UAS-Gad1/+; right side: tbphΔ23/tbphΔ23;D42-GAL4/UAS-Gad1) and Δtb-TB (left 
side: elav-GAL4,tbphΔ23/tbphΔ23,UAS-TBPH; right side: tbphΔ23/tbphΔ23,UAS-TBPH;D42-GAL4/+). n = 25. 
(e) Climbing assay on 4 days old adult flies compare w1118, tbhypo-GFP (elav-GAL4,tbphΔ23/UAS-GFP;UAS-Dcr-
2,TBPH-RNAi/+) and tbhypo-Gad1 (elav-GAL4,tbphΔ23/ + ;UAS-Dcr-2,TBPH-RNAi/UAS-Gad1). n = 100. (f) 
Confocal images of third instar NMJ terminals, muscle 6/7 second segment stained with anti-HRP (in green) 
and anti-GluRIIA (in red) in w1118, Elav-Δtb-GFP and Elav-Δtb-Gad1. (g) Confocal images of third instar NMJ 
terminals in muscle 6/7 second segment stained with anti-HRP (in green) and anti-Dlg (in red) in w1118, Elav-
Δtb-GFP and Elav-Δtb-Gad1. (h-i) Quantification of GluRIIA intensity and Dlg intensity, n > 200 boutons. 
**p < 0.01, ***p < 0.001 calculated by one-way ANOVA. Error bars SEM. Scale bar 5 µm.
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Gad1 activity in the Drosophila glia is required for the postsynaptic clustering of glutamate 
receptors at the neuromuscular synapses. Considering that the normal function of TBPH is 
also required in the Drosophila glia to prevent synaptic defects, we decided to analyze whether Gad1 activ-
ity was necessary in these tissues to prevent the neurological phenotypes described in TBPH minus flies18. 
Strikingly, we observed that the expression of Gad1 with the glial driver repo-GAL4 in TBPH minus flies 
(tbph∆23/∆23;repo-GAL4/UAS-Gad1) was able to completely restore the locomotive defects observed in L3 larvae 
(Fig. 3a). Interestingly, we found that the expression of Gad1 in the peripheral glia with gliotactin-GAL426,27 sig-
nificantly managed to recover the motility of the mutant flies indicating that the proper function of these special-
ized cells was sufficient to promote an amelioration of the peristaltic phenotypes. Anatomically, we found that the 
recovery of fly motility was accompanied by the re-formation of the glutamate receptor field at the postsynaptic 
neuromuscular synapses (Fig. 3b and c). In contrast, the expression of Gad1 was not able to regenerate the post-
synaptic distribution of Dlg or induce the glial wrapping of neuromuscular axons (Supplementary Fig. S4a–d,f 
and i). At the presynaptic level, glial Gad1 expression was not able to promote the growth of motoneuron termi-
nal axons or the recovery of Syntaxin (Supplementary Fig. S4e,g,h, j and k). In agreement with these results, we 
observed that the targeted suppression of Gad1 in the Drosophila glia using a specific RNAi under repo-GAL4 
(UAS-Dcr-2/+;;repo-GAL4/GAD-RNAi) provoked serious locomotive problems and strongly disrupted the 
postsynaptic distribution of the glutamate receptors at the NMJ (Fig. 3d–g). The intracellular localization of Dlg 
instead, seemed not to be affected by the glial absence of Gad1 (Fig. 3h and i). Identically, the silencing of Gad1 
did not affect motoneuron axon growth or presynaptic levels of the transmembrane proteins Syntaxin (Syx) or 
Bruchpilot (Brp) (Supplementary Fig. S4l–q) revealing an unexpected role of Gad1 in the glia, i.e. supporting 
synaptogenesis.
TBPH minus flies present neurotoxic levels of extracellular glutamate. Alterations in the metab-
olism of glutamate, the main excitatory neurotransmitter in Drosophila CNS and principal substrate of Gad1, 
had been previously associated with the neuromuscular defects observed in Gad1 loss-of-function embryos22. 
We therefore investigated whether TBPH minus flies presented altered levels of extracellular glutamate. In these 
experiments, we quantified the amounts of the neurotransmitter circulating in the hemolymph of mature L3 
larvae and found that TBPH mutant flies presented a 1.5-fold increase in the levels of glutamate compared to 
wild-type controls. Similar results, were obtained upon suppression of Gad1 in Drosophila neurons by RNAi 
(elav-GAL4/+; GAD-RNAi) (Fig. 4a). To determine whether the excess of glutamate revealed in the extracellular 
space was causing neurotoxicity in TBPH mutant flies we utilized memantine, a very well characterized glutamate 
receptor antagonist already used to treat patients with Alzheimer’s disease28,29. We found that memantine-fed 
TBPH minus L3 larvae consistently showed improved movement at the end of the larval period compared to 
untreated mutants or wild-type controls (Fig. 4b). An identical approach using lithium chloride (LiCl), a less spe-
cific antagonist of hyperactivated glutamate receptors, similarly rescued the TBPH minus locomotive problems 
described in L3 larvae (Fig. 4c). The beneficial effect of these drug treatments became more evident in experi-
ments performed in a TBPH hypomorphic background (Fig. 4d). Indeed, we found that 50μM of memantine 
administered to flies expressing TBPH-RNAi in neurons (UAS-Dcr-2/+;tbph∆23,elav-GAL4/+;TBPH-RNAi/+) 
was sufficient to allow a complete reconstitution of the GluRIIA fields at the postsynaptic membranes (Fig. 4e,f). 
This suggested that the excess of glutamate detected in TBPH mutant larvae may have contributed to the neuro-
degeneration through a persistent activation of their own receptors. Bearing in mind that Gad1 catalyzes the for-
mation of GABA from glutamate, we decided to analyze if defects in the activation of the inhibitory GABAergic 
pathways contributed to TBPH mutant phenotypes. For these experiments we treated TBPH null flies with differ-
ent concentrations of GABA30 and found that the increase in GABA was unable to modify the reduced locomotive 
phenotypes of TBPH mutant flies (Supplementary Fig. S5c).
Gad1 dysregulation is conserved in human cells derived from ALS patients. Interestingly, we 
found that the suppression of TDP-43 expression in human neuroblastoma SK-N-BE cells induced a similar 
reduction in the expression levels of GAD67, the Drosophila Gad1 homolog protein, indicating that these mod-
ifications were conserved (Fig. 5a and Supplementary Fig. S6b). These results would also suggest that analogous 
regulatory mechanisms might be affecting ALS patients. To test this hypothesis, we reprogrammed primary fibro-
blasts from ALS patients containing mutations in TDP-43 (n = 3: patient #1 carrying G287S mutation; patient #2 
carrying G294V mutation and patient #3 carrying G378S mutation) to obtain iPSC lines using a protocol based 
on the transduction of Sendai virus (SeV) vectors containing four reprogramming factors31. These vectors are 
non-integrating and remain in the cytoplasm, allowing the production of iPSCs free of exogenous sequences. 
iPSC lines reprogrammed from unaffected adult skin fibroblasts (n = 2: control #1 and control #2) were used 
as controls. Four weeks after reprogramming, colonies with pluripotent morphology were selected for further 
expansion and analysis. We found that in iPS cells derived from ALS patients, the levels of GAD67 protein 
resulted clearly downregulated or even absent when compared with the two controls (Fig. 5b and Supplementary 
Fig. S6c). In addition, ALS iPSCs (from patient #3) and iPSCs from control (#1) were differentiated into spinal 
motor neurons (MNs) using a multistep protocol already described for human iPSCs32. We performed western 
blot analysis to evaluate the expression of GAD67 in ALS MNs compared to control and we confirmed a clear 
downregulation of GAD67 protein also in MNs (Fig. 5c and Supplementary Fig. S6d). Remarkably, quantitative 
PCR analysis revealed that the levels of GAD67 mRNA were also reduced in MNs (Fig. 5d) strongly supporting a 
preserved role for this enzyme in the neurodegenerative process behind ALS.
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Figure 2. The reduction of Gad1 in neurons triggers postsynaptic assembly defects. (a) Number of peristaltic 
waves of Ctrl (left side: UAS-LacZ/elav-GAL4 and right side:UAS-Dcr-2/+;UAS-LacZ/+;D42-GAL4/+) and GADi 
(left side: elav-GAL4/+;GAD-RNAi/+ and right side: UAS-Dcr-2/+;;D42-GAL4/GAD-RNAi) larvae. n = 20. 
(b) Climbing assay on adult flies at day 4 of Ctrl and GADi on the left using elav-GAL4 and on the right using 
D42-GAL4. n = 100. (c) Confocal images of third instar NMJ terminals in muscle 6/7 second segment stained 
with anti-HRP (in green) and anti-GluRIIA (in red) in Ctrl and GADi (using elav-GAL4). (d) Quantification 
of GluRIIA intensity in Ctrl and GADi. n = 200 boutons. (e) Confocal images of third instar NMJ terminals in 
muscle 6/7 second segment stained with anti-HRP (in green) and anti-Dlg (in red) in Ctrl and GADi (using elav-
GAL4). (f) Quantification of Dlg intensity in Ctrl and GADi. n = 200 boutons. ***p < 0.001, calculated by T-test. 
Error bars SEM. Scale bar 5 µm.
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Figure 3. The glial activity of Gad1 is sufficient to ensure the postsynaptic clustering of the GluRIIA. (a) Number 
of peristaltic waves of Ctrl (left side: tbphΔ23/+; repo-GAL4,UAS-GFP/+; right side: tbphΔ23,gliotactin-GAL4/+; 
UAS-GFP/+), Δtb-GFP (left side: tbphΔ23/tbphΔ23;repo-GAL4/UAS-GFP; right side: tbphΔ23,gliotactin-GAL4/
tbphΔ23;UAS-GFP/+) and Δtb-Gad1 (left side: tbphΔ23/tbphΔ23;repo-GAL4/UAS-Gad1; left side: tbphΔ23, gliotactin-
GAL4/ tbphΔ23;UAS-GFP/+). n = 25. (b) Confocal images of third instar NMJ terminals in muscle 6/7 second 
segment stained with anti-HRP (in green) and anti-GluRIIA (in red) in Ctrl, Δtb-GFP and Δtb-Gad1 (using repo-
GAL4). (c) Quantification of GluRIIA intensity. n > 200 boutons. (d) Number of peristaltic waves of Repo-Ctrl (UAS-
Dcr-2/+;UAS-LacZ/ + ;repo-GAL4/+) and Repo-GADi (UAS-Dcr-2/+; +/+; repo-GAL4/GAD-RNAi) larvae. 
n = 20. (e) Climbing assay on adult flies at day 4 of Repo-Ctrl and Repo-GADi. n = 100. (f) Confocal images of third 
instar NMJ terminals in muscle 6/7 second segment stained with anti-HRP (in green) and anti-GluRIIA (in red) in 
Repo-Ctrl and Repo-GADi. (g) Quantification of GluRIIA intensity. n > 200 boutons. (h) Confocal images of third 
instar NMJ terminals in muscle 6/7 second segment stained with anti-HRP (in green) and anti-Dlg (in red) in Repo-
Ctrl and Repo-GADi. (i) Quantification of Dlg intensity. n > 200 boutons. ns = not significant *p < 0.05, ***p < 0.001 
calculated by one-way ANOVA in (a and c) and T-test in (d,e,g and i). Error bars SEM. Scale bar 5 µm.
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Discussion
Alterations in motoneuronal excitability derived from defects in the activity of strategic enzymes required for 
the synthesis and metabolism of the neurotransmitters have been previously associated with the pathogenesis of 
ALS18,33,34. However, the interpretation of the results reported has always proved difficult due to the lack of experi-
mental evidence connecting the molecular modifications observed with the physiopathogenesis of the disease. To 
fill this gap, we utilized the Drosophila system in which we have previously described that the suppression of the 
TDP-43 homolog protein closely reproduces the molecular characteristics observed in ALS14. Subsequently, our 
analysis showed that Gad1, the enzyme catalyzing the decarboxylation of glutamate to GABA, appeared down-
regulated in TBPH minus fly heads compared to wild-type controls and demonstrated that the genetic rescue of 
Gad1 deficiencies in TBPH-null presynaptic neurons or glia was sufficient to recover flies motility, extracellular 
glutamate levels and the postsynaptic distribution of the glutamate receptors at the neuromuscular junctions. 
Moreover, we found that defects in Gad1 levels associated with pathological modifications in TDP-43 were con-
served in human cell lines and present in iPSC-derived motoneurons from ALS patients, linking these events with 
the potential mechanisms of the disease.
Defects in Gad1 activity due to TBPH loss induced glutamate excitotoxicity in flies. Although 
it is commonly accepted that excitotoxicity plays an important role in the pathogenesis of ALS, it was not clear 
so far whether brains affected by TDP-43 dysfunctions present alterations in the metabolism of glutamate or 
if these alterations are neurotoxic. In this respect, we found that null alleles of TBPH show increased levels of 
Figure 4. Gad1 downregulation provokes glutamate excitotoxicity in TBPH mutant flies. (a) Glutamate relative 
concentration in the hemolymph of third instar larvae: on the left graph in w1118, ∆tb-23 (tbphΔ23/Δ23) and Elav-
GADi (elav-GAL4/+;GAD-RNAi/+) and on the right graph the glutamate levels in w1118, Elav-Repo-ΔtbGFP 
(elav-GAL4,tbphΔ23/tbphΔ23;repo-GAL4,UAS-GFP/+) and Elav-Repo-Δtb-Gad1 (elav-GAL4,tbphΔ23/
tbphΔ23;repo-GAL4,UAS-GFP/UAS-Gad1). Left graph n = 3, right graph n = 2. The axis of ordinates showed 
the ratio between the chosen fragment of the fragmentation spectra of glutamic acid and isotopic labelled 
glutamic acid. (b) Number of peristaltic waves of L3 larvae fed in food containing 50 µM Memantine “D-Drug” 
or containing the vehicle only “V-Vehicle”, in w1118 and ∆tb-23 (tbphΔ23/Δ23). n = 20. (c) Number of peristaltic 
waves of L3 larvae fed in food containing 5 mM Lithium chloride (LiCl) “D-Drug” or containing the vehicle 
only “V-Vehicle”, in w1118 and ∆tb-23 (tbphΔ23/Δ23). n = 20. (d) Number of peristaltic waves of L3 larvae fed in 
food containing 50 µM Memantine “D-Drug” or containing the vehicle only “V-Vehicle”, in Elav-Ctrl (UAS-
Dcr-2/+;elav-GAL4,tbphΔ23/UAS-LacZ) and Elav-TBi (UAS-Dcr-2/+;elav-GAL4,tbphΔ23/+;TBPH-RNAi/+). 
n = 20. (e) Confocal images of third instar NMJ terminals in muscle 6/7 second segment stained with anti-
HRP (in green) and anti-GluRIIA (in red) in Elav-Ctrl and Elav-TBi with and without the treatment. (f) 
Quantification of GluRIIA intensity. n > 200 boutons. ns = not significant *p < 0.05, ***p < 0.001 calculated by 
one-way ANOVA. Error bars SEM. Scale bar 5 µm.
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circulating glutamate in the hemolymph. Perhaps more interestingly, these results were confirmed by the suppres-
sion of Gad1 activity exclusively in neurons by expression of a specific RNAi against the enzyme. Moreover, we 
found that TBPH minus flies showed an increased sensitivity to the neurotransmitter (Supplementary Material, 
Fig. S5b)30, confirming the incidence of a higher glutamate signaling in these flies. In agreement with this hypoth-
esis, we reported that memantine, a specific glutamate receptor antagonist, significantly improved the locomotive 
ability of TBPH-null larvae and stimulated the postsynaptic recovery of the glutamate receptors in the NMJs of 
TBPH-minus hypomorphic alleles (Fig. 4b,e,f). These results indicate that TBPH function is necessary to prevent 
Figure 5. The dysregulation of Gad1 is conserved in human cell lines and iPSCs ALS patients derived. (a) 
Western blot analysis on human neuroblastoma (SK-N-BE) cell line probed for anti-GAD1, anti-GAPDH 
and anti-TDP in siTDP (TDP silenced) and siLuc (Luciferase ctrl). The same membrane was probe with 
the three antibodies and the bands of interest were cropped. Quantification of normalized protein amount 
was reported below each lane, n = 3. (b) Western blot analysis on human iPSCs probed for anti-GAD1 and 
anti-GAPDH in three clones derived from three different ALS patients (ALS patient #1 carrying the G287S 
mutation; ALS patient #2 carrying the G294V mutation; ALS patient #3 carrying the G378S mutation) and in 
two clones derived from two different healthy subjects (Ctrl #1 Ctrl #2). The same membrane was probe with 
the two antibodies and the bands of interest were cropped. In the two upper panels were reported two different 
exposition of anti-GAD1 signal. Quantification of normalized protein amount was reported below each lane. 
n = 3. (c) Western blot analysis probed for anti-GAD1 and anti-GAPDH on human differentiated motoneurons 
derived from iPSCs of an ALS patient (ALS patient #3 carrying the G378S mutation) and a healthy control (Ctrl 
#1 clone ND41864). The same membrane was probe with the three antibodies and the bands of interest were 
cropped. In the two upper panels were reported two different exposition of anti-GAD1 signal. Quantification 
of normalized protein amount was reported below each lane. (d) Real time PCR of Gad1 transcript levels 
normalized on Gapdh (housekeeping) in human differentiated motoneurons derived from iPSCs of an ALS 
patient (ALS patient #3 carrying the G378S mutation) and a healthy control (Ctrl #1 clone ND41864). n = 2, 
**p < 0.01 calculated by T-test. Error bars SEM.
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9Scientific REPORTs |  (2018) 8:1809  | DOI:10.1038/s41598-018-19802-3
glutamatergic excitotoxicity by maintaining normal levels of Gad1 activity. In agreement with this interpretation, 
previous experiments performed in Drosophila embryos had shown that Gad1 activity affects the postsynaptic 
organization of glutamate receptors at neuromuscular junctions through the regulation of the neurotransmitter 
release22.
Considering that Gad1 activity is also required to synthesize GABA, we analyzed whether defects in this neu-
rotransmitter played any role in the neurological phenotypes caused by the absence of TBPH. We found that the 
administration of GABA (as described in Drosophila models of Fragile X syndrome30) was ineffective to reverse 
the locomotive alterations described in TBPH minus alleles (Supplementary Fig. S5c). Alike, the administra-
tion of the GABAB antagonist CGP5584530 was unable to modify the TBPH minus phenotypes (Supplementary 
Fig. S5d). Although, these experiments did not allow to exclude the eventual role of the GABA signaling in TBPH 
minus defects, our results support the notion that the excessive production of glutamate was behind these neu-
rological alterations.
How does TBPH regulate Gad1 levels? Despite, the strong genetic and biochemical correlations defined 
in this study, we did not detect direct physical interactions between TBPH and the messenger of Gad1 by 
co-immunoprecipitation17,21, suggesting that these regulatory mechanisms may involve some other intermediate 
molecules. Concerning this issue, TBPH regulates many different targets and is involved in numerous aspects 
of RNA metabolism through specific RNA-binding proteins some of which may be directly influencing the sta-
bility or expression levels of Gad1. Indeed, we observed that Gad1 mRNA levels were affected by the absence of 
TBPH indicating that transcription or splicing defects may have a role in the downregulation of this enzyme35–37. 
Alternatively, alterations in synaptic transmission, cytoplasmic transport or autophagy induced by the absence 
of TBPH could affect the vesicular localization of Gad1, its intracellular localization or its activity38–40. Defects 
in TBPH could also downregulate Gad1 through the activation of stress responsive pathways that mediate the 
enzymatic cleavage and degradation of this protein when cells go to apoptosis40. Additional experiments would 
be required to address these issues.
The association between Gad1 levels and TDP-43 dysfunction is conserved. Defects in the human 
Gad1 homolog proteins GAD67 and GAD65 were found in patients suffering from different neurodegenerative 
diseases including Parkinson, Huntington and Alzheimer’s41–43 or cognitive disorders like idiopathic autisms or 
schizophrenia44–46, suggesting that a tight regulation of this enzyme is critical to preserve normal brain func-
tioning. In the case of ALS, different lines of evidence suggest that glutamate-induced cytotoxicity might play an 
important role in the development of the disease33. Interestingly, we found that the reduction of TDP-43 expres-
sion in human neuroblastoma cells induced similar modifications in the protein levels of the human homolog 
protein GAD67. More strikingly, we found identical modifications in iPSC-derived motoneurons obtained from 
patients carrying TDP-43 mutations and suffering from the disease, indicating that these regulatory mechanisms 
are conserved. Analogously, our results imply that similar defects in the regulation of the neurotransmitter could 
disturb the synaptic organization of motoneuron terminals in affected patients and suggest that the pharmaco-
logical modulation of the glutamate receptors or an excessive glutamate signaling might be beneficial to limit the 
neurodegenerative process in ALS.
Material and Methods
Fly strains. The genotype of the flies used in this work are indicated below:
w1118 - w;tbphΔ23/CyOGFP - w;tbphΔ142/CyOGFP - w;elav-GAL4/CyOGFP - w;D42-GAL4 - repo-GAL4/
TM3,Sb - w;;tubulin-GAL4/TM2 - w;tubulin-GAL80TS - UAS-Dcr-2 - gliotactin-GAL4/CyOGFP (gifted by Dr. 
Vanessa Auld) - w;UAS-mCD8::GFP - w;UAS-TBPH - w;Mi[MIC]Gad1MI09277/TM3,Sb,Ser - UAS-Gad1/TM3,Sb 
(gifted by Dr. Andreas Prokop) - UAS-GAD-RNAi/TM3Sb (#28079, Bloomington) - UAS-TBPH-RNAi/TM6b 
(#ID38377, VDRC) - UAS-LacZ/CyO.
Larval movement and Climbing assay. The protocol previously described in14 has ben used.
Drug treatment. Memantine 4.6 mM, Lithium chloride 1 M, GABA 8 M and CGP55845 100 mM were pre-
pared and then were diluted during the fly food preparation in accordance to the final concentration required. 
Control groups have been fed in a standard food containing vehicle only. Parental flies have been maintained 
24 hours in the tubes to allow the embryo laying. Embryos were grown to obtain third instar larvae used for the 
further analysis.
Hemolymph extraction and sample preparation. Hemolymph was pooled from 15–18 third instar 
larvae to obtain a final volume of 2 µl. The two extremities of larvae were pinned, then transferred in a 0.5 ml tube 
with a 3 mm cut on the bottom and inserted in a 1.5 ml tube. Tubes were centrifuged at top speed for 20 seconds 
and equal volumes of the hemolymph drop in the bottom of 1.5 ml tube were immediately collected in a new tube 
and stored at −80 °C until analysis.
4 μl of the hemolymph and standard samples, were diluted with 200 μl of internal standard solution (10µM 
L-glutamic acid-2,3,3,4,4-d5, Merck KGaA, Germany) in 60% acetonitrile - 40% water with 10 mM NH4OAc. 
After centrifugation, 5 μl of this solution were injected into the LC–MS/MS.
Gradient elution profile and instruments. Mobile phase “A” and “B” consisted of 0.1% formic acid in 
water (LC–MS grade) and 0.1% formic acid in acetonitrile (LC–MS grade), respectively. The gradient elution 
profile was chosen as follows: 0 min: 10% A, 3 min: 10% A, 13.00 min: 100% A, 20 min: 100% A, 21 min: 10% A, 
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31 min: 10% A. The HPLC system consisted of a Gilson 234 autosampler (Gilson Inc., Middleton, WI), Gilson 
306 Binary Pump, and a Thermostatted Column Compartment (Agilent Technologies, Morges, Switzerland). 
Chromatographic retention was obtained using a hydrophilic interaction liquid chromatography (HILIC) col-
umn (ZIC®-HILIC, 150 × 2.1 mm i.d., 3.5μm, Merck KGaA, Germany) at 30 °C run at 250ul/min. Eluates were 
detected using an amaZonSL ion trap mass spectrometer (Bruker Daltonik GmbH, Germany) in the positive 
electrospray ionisation (ESI) mode. The ion spray voltage was set at 4500 V and the source temperature at 200 °C. 
Data were acquired monitoring the m/z 148.1/84.1 transition (L-Glu) and the 153.1/89.1 transition (d5-L-Glu 
internal standard) and analyzed using the software Compass Data Analysis 4.2 (Bruker).
Immunohistochemistry. The neuromuscular junctions of third instar larvae were dissected as described 
in17. Dilutions of antibodies used are reported here: anti-HRP (Jackson 1:150), anti-GFP (Life Technologies 1:200), 
anti-GluRIIA 8B4D2c (DSHB 1:15), anti-Dlg 4F3c (DSHB 1:250), anti-Syx 8C3s (DSHB 1:15), anti-Bruchpilot 
(DSHB 1:50), anti-HRP-Cy3 (Jackson 1:150), Alexa-Fluor® 488 (mouse or rabbit 1:500) and Alexa- Fluor® 555 
(mouse and rabbit 1:500).
Acquisition and quantification of confocal images. In each experiment, the genotypes of interest were 
processed simultaneously and the images were acquired using the same settings. Images of muscle 6 and 7 on second 
abdominal segment were acquired using the LSM Zeiss Software on a Zeiss 510Meta confocal microscope (63 × oil 
lens) and then analyzed using ImageJ (Wayne Rasband, NIH). For the quantification of pre and postsynaptic mark-
ers, samples were double labelled with anti-HRP and the marker of interest: the ratio between the mean intensity 
of the marker and the HRP was calculated for each bouton of the terminal. The quantification of glial area was cal-
culated analyzing the ratio between the area occupied by glial tissue versus the area of the presynaptic terminal17,18.
Bi-dimensional protein separations (IEF/SDS-PAGE) and mass-spectrometry analysis. Three 
independent fly head protein extractions were performed, and protein concentrations were evaluated by 
Bradford. Protein extractions were TCA precipitated, solubilized in isoelectrofocusing (IEF) rehydration solu-
tion containing 0.6% IPG buffer pH 3-11 NL (GE Healthcare Bio-sciences AB) and separated according to their 
isoelectric point on nonlinear immobilized pH-gradient strips (pH3-11 NL) with a length of 13 cm. The isoelec-
trofocusing program was: 50 V for 4 hours, 500 V for 1 hour, 1,000 V for 2 hours, and 8,000 V up to 48,000 V × h. 
Focused strips were equilibrated with 2.5 ml of the following solutions: 6 M urea, 30% glycerol, 50 mM Tris–HCl 
(pH 8.8), 2% SDS, 25 mg DTT and bromophenol blue; then 6 M urea, 30% glycerol, 50 mM Tris–HCl (pH 8.8), 2% 
SDS, 62.5 mg iodoacetamide and bromophenol blue. The strips were subjected to electrophoretic separation on 
14% SDS-polyacrilamide gels (18 × 20 × 0.15 cm) run at 12 mA O.N. The gels were then fixed and stained (0.12% 
Colloidal G-250 Coomassie Blue). Spot intensity acquisitions were performed at 300 dpi and in conditions of 
linear response in an Epson Expression 1680 Pro scanner. Values of pI were calculated according to the pH curve 
of the pH gradient strips provided by the supplier (GE Life Sciences), while protein molecular masses were calcu-
lated from the semi-logarithmic curves of log10 molecular mass versus migration distance. The images acquired 
for each of the gels (triplicates) were analyzed with the Redfin 3 program (Ludesi AB, Lund, Sweden) which 
includes all-to-all spot matching and normalization according to the total protein content, taken as the sum of 
the intensities of all the spots contained in each gel. Proteins were considered to be differentially expressed when 
their mean spot intensity differed by >1.5-fold between groups, with p < 0.05. Relevant spots were excised and 
sent to the proteome and mass spectrometric service Proteome Factory AG (Proteome Factory AG, Germany) for 
nanoLC-ESI-MS/MS analysis.
Western blot on Drosophila brains, transfected neuroblastoma SK-N-BE, and iPSC lines. 
Drosophila larval brains were homogenized in lysis buffer (10 mM Tris, 150 mM NaCl, 5 mM EDTA, 5 mM 
EGTA, 10% Glycerol, 50 mM NaF, 5 mM DTT, 4 M Urea, pH 7.4, plus Protease Inhibitors (Roche #11836170001)).
SK-N-BE and iPS cell lines, were resuspended in iced PBS plus Protease Inhibitors and subjected to sonication 
(Biorupture, Diagenode).
Lysates were quantified (#Q33211, Invitrogen), separated on SDS-PAGE and transferred to nitrocellulose 
membrane (#NBA083C Whatman Protran). Blots were blocked with 5% non-fat dry milk or 5% BSA, if required 
by antibody supplier, in TBS-T (Tris-buffered saline, 0.1% Tween 20).
The panel of primary antibodies used includes: anti-Flag M5 (F4042 Sigma 1:10,000), GAD1 (#5305 Cell 
Signaling 1:2,000), anti tubulin DM1A (#CP06 Calbiochem 1:5,000) and the anti GAPDH (#sc-47724 Santa 
Cruz 1:2,000). Secondary antibody incubation was performed with anti-mouse HRP conjugated or anti-rabbit 
HRP conjugated (#32430; #32460 Pierce 1:1000). SuperSignal West Femto Maximum Sensitivity Substrate Kit 
(#PR34095 Pierce) was used for detection and protein quantification was performed using ImageJ.
RT-PCR. Third instar larval brains and motoneurons were mechanically squeezed to proceed with RNA 
extraction, using RNeasy®Microarray MiniKit (50) (#73304 Qiagen) and the QIAshredderTM kit(50) (#79654 
Qiagen). The RNA was than treated with DNase (#M6101 Promega) and oligo-dT retro-transcripted with 
SuperScript® III First-Strand Synthesis (#18080051 ThermoFisher). Gene specific primers were designed for 
amplification:
Gad1: 5′GAATTCAGAGCATAGAAGCCACCG3′ and 5′CAACTGGCTCTTCATCTTCTCCTG3′
Rpl11 5′CCATCGGTATCTATGGTCTGGA3′ and 5′CATCGTATTTCTGCTGGAACCA3′
Gapdh: 5′CTGGGCTACACTGAGCACC3′ and 5′AAGTGGTCGTTGAGGGCAATG3′
Gad67: 5′CCTCAACTATGTCCGCAAGAC3′ and 5′TGTGCGAACCCCATACTTCAA3′
The quantification was calculated according the ΔΔCT equation and then normalized on control genotype.
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Cell culture and RNA interference. SK-N-BE neuroblastoma cell line was cultured in standard condi-
tions in DMEM-Glutamax (#31966-021, Thermo Fisher Scientific) supplemented 10% fetal bovine serum and 
1 × antibiotic-antimycotic solution (#A5955; Sigma). RNA interference of TDP-43 was achieved using HiPerfect 
Transfection Reagent (#301705, Qiagen) and siRNA specific for human TDP43 (5′-gcaaagccaagaugagccu-3′); as 
control siRNA for Luciferase was used (5′-uaaggcuaugaagagauac-3′; Sigma). Immediately before transfection 
2–4 × 105 cells were seeded in 6-well plates in 1.4 ml of medium containing 10% fetal serum. A volume of 3 µl 
of each siRNA (40 µM solution in water), was added to 91 µl of Opti-MEM I reduced serum medium (#51985-
026, Thermo Fisher Scientific), incubated 5 minutes at room temperature and subsequently 6 µl of HiPerfect 
Transfection Reagent were added. The silencing procedure was performed again after 24 and 48 hours.
Human iPSC Culture and MN differentiation. The studies involving human samples were conducted in 
compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and with national 
legislation and institutional guidelines. Fibroblasts were generated from dermal biopsies (Eurobiobank) follow-
ing informed consent (ethical committee approved at the IRCCS Foundation Ca’ Granda Ospedale Maggiore 
Policlinico). Fibroblasts from dermal biopsies of ALS patients (n = 3: patient #1 carrying G287S mutation; patient 
#2 carrying G294V mutation and patient #3 carrying G378S mutation) and control subjects (n = 2: control #1 
and control #2) were reprogrammed into iPSCs using CytoTune®-iPS 2.0 Sendai Reprogramming Kit (Life 
Technologies)31, containing Sendai virus (SeV) vectors in which four reprogramming factors (OCT4, SOX2, 
c-Myc, and KLF4) were cloned. iPSC colonies with embryonic stem cell (ESC)-like morphology were cultured 
and expanded on Matrigel-coated dishes (BD Biosciences) in Essential E8 media (Life Technologies). All cell 
cultures were maintained at 37 °C, 5% CO2.
iPSCs were differentiated into MNs using a multistep protocol as described32.
Statistical analysis. The statistical analysis was performed with Prism (GraphPad, USA) version 7.0.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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